ArticleMolecular neurobiology2026
Endothelial miR-7052 Safeguards Blood-Brain Barrier Integrity During Endotoxemia by Co-repressing ANGPT2 and PDE5A.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated inflammation compromises the blood-brain barrier (BBB), yet the endothelial microRNA circuitry that buffers barrier failure remains poorly defined. Here we identify endothelial miR-7052 as a stress-suppressed regulator of BBB integrity. In human and murine brain microvascular endothelium, lipopolysaccharide (LPS) reduces mature miR-7052 via a VEGFR2-JNK signaling arm. Loss of miR-7052 de-represses ANGPT2 and PDE5A, attenuates Tie2 signaling, and perturbs cGMP homeostasis, yielding disrupted junctional continuity, reduced transendothelial electrical resistance (TEER), and increased macromolecular flux. Restoring miR-7052 increases TEER, lowers 4- and 70-kDa tracer permeability, and preserves ZO-1/claudin-5 organization. Mechanistically, dual-luciferase reporters confirm direct repression of ANGPT2 and PDE5A; prime-editing of endogenous 3'UTR seed sites abolishes miR-7052 control and eliminates miR-dependent changes in transcript half-life. Epistasis tests position both targets downstream: recombinant ANGPT2 partially reverses miR-7052-mediated protection, whereas pharmacological PDE5 inhibition phenocopies barrier stabilization. In vivo, endothelial-specific AAV9 delivery of miR-7052 limits LPS-evoked BBB leakage and reduces microvessel ANGPT2 with concordant reinforcement of BBB transcripts. Together, these data establish miR-7052 as a nodal controller coupling inflammatory receptor input to multi-target suppression of permeability drivers, nominating miR-7052 replacement and combinatorial targeting of the ANGPT2/Tie2 and PDE5A/cGMP axes as therapeutic strategies to preserve the BBB in sepsis.
Indexed as
Identifiers
41677948What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.